Clinical Trials

NCT Number: NCT05888532 Phase: PHASE1|PHASE2 Trial Summary: This is a first-in-human phase I/II imaging study of 64Cu-GRIP B PET in patients with advanced genitourinary (GU) malignancies. The tracer is designed to detect extracellular granzyme B as it is secre – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym:

NCT Number: NCT05219500 Phase: Phase 2 Trial Summary: The treatment regimen will consist of 4 doses of 225Ac-PSMA- – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Fusion Pharmaceuticals Inc. Acronym: TATCIST

NCT Number: NCT05348577 Phase: Phase 3 Trial Summary: This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mC – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): AstraZeneca Acronym: CAPItello280

NCT Number: NCT05081193 Phase: Phase 2 Trial Summary: Previous studies of high dose testosterone therapy given intramuscularly to men with metastatic castrate resistant prostate cancer suggest that high serum levels of testosterone ma – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Acronym:

NCT Number: NCT05245006 Phase: Phase 1 Trial Summary: CD46 is an exciting new therapeutic target in prostate cancer, with the antibody drug conjugate FOR46 under investigation in phase I clinical trials. The hypothesis of the study is – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Robert Flavell, MD, PhD Acronym:

NCT Number: NCT05283330 Phase: Phase 1 Trial Summary: A Phase 1 SAD/MAD dose escalation and expansion study to determine the safety and effectiveness of 212Pb-DOTAM-GRPR1 in subjects with various GRPR-exp – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Orano Med LLC Acronym:

NCT Number: NCT05413850 Phase: Phase 1|Phase 2 Trial Summary: To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Blue Earth Therapeutics Ltd Acronym:

NCT Number: NCT05479578 Phase: Phase 1 Trial Summary: This phase I trial tests the safety and side effects of cyclophosphamide given together with dexamethasone in treating patients with castration resistant prostate cancer that has s – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rashmi Verma, MD Acronym:

NCT Number: NCT04946370 Phase: Phase 1|Phase 2 Trial Summary: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym:

NCT Number: NCT04986423 Phase: Phase 2 Trial Summary: This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Zenith Epigenetics Acronym: